Literature DB >> 12821493

Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents.

Manuel Cuenca-Estrella1, Alicia Gomez-Lopez, Emilia Mellado, Maria J Buitrago, Araceli Monzón, Juan L Rodriguez-Tudela.   

Abstract

The antifungal susceptibility results for 32 clinical isolates of Scopulariopsis brevicaulis are presented. Flucytosine and itraconazole were inactive in vitro, and MICs of amphotericin B, voriconazole, and terbinafine for all isolates were high, with geometric means of 13, 25.8, and 14.4 microg/ml, respectively.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12821493      PMCID： PMC161832          DOI： 10.1128/AAC.47.7.2339-2341.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Invasive Scopulariopsis in the immunocompromised host.

Authors:  J P Neglia; D D Hurd; P Ferrieri; D C Snover
Journal:  Am J Med       Date:  1987-12       Impact factor: 4.965

2.  Scopulariopsis brevicaulis skin lesions in an AIDS patient.

Authors:  J Dhar; P B Carey
Journal:  AIDS       Date:  1993-09       Impact factor: 4.177

3.  Fungal keratitis caused by Scopulariopsis brevicaulis: successful treatment with topical amphotericin B and chloramphenicol without the need for surgical debridement.

Authors:  A J Lotery; J R Kerr; B A Page
Journal:  Br J Ophthalmol       Date:  1994-09       Impact factor: 4.638

4.  Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi.

Authors:  R C Summerbell; J Kane; S Krajden
Journal:  Mycoses       Date:  1989-12       Impact factor: 4.377

5.  Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals.

Authors:  A Tosti; B M Piraccini; C Stinchi; S Lorenzi
Journal:  Br J Dermatol       Date:  1996-11       Impact factor: 9.302

Review 6.  Deep tissue infections caused by Scopulariopsis brevicaulis: report of a case of prosthetic valve endocarditis and review.

Authors:  R Q Migrino; G S Hall; D L Longworth
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

7.  The spectrum of non-Candida fungal infections following bone marrow transplantation.

Authors:  V A Morrison; R J Haake; D J Weisdorf
Journal:  Medicine (Baltimore)       Date:  1993-03       Impact factor: 1.889

8.  Opportunistic Scopulariopsis pneumonia in an immunocompromised host.

Authors:  L J Wheat; M Bartlett; M Ciccarelli; J W Smith
Journal:  South Med J       Date:  1984-12       Impact factor: 0.954

9.  Surgical and long-term antifungal therapy for fungal prosthetic valve endocarditis.

Authors:  D D Muehrcke; B W Lytle; D M Cosgrove
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

10.  Scopulariopsis endocarditis associated with Duran ring valvuloplasty.

Authors:  L O Gentry; M M Nasser; M Kielhofner
Journal:  Tex Heart Inst J       Date:  1995
View more
  20 in total

1.  Scopulariopsis, a poorly known opportunistic fungus: spectrum of species in clinical samples and in vitro responses to antifungal drugs.

Authors:  Marcelo Sandoval-Denis; Deanna A Sutton; Annette W Fothergill; Josep Cano-Lira; Josepa Gené; C A Decock; G S de Hoog; Josep Guarro
Journal:  J Clin Microbiol       Date:  2013-09-11       Impact factor: 5.948

2.  In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Maria J Buitrago; Emilia Mellado; Guillermo Garcia-Effron; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Guillermo Garcia-Effron; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species.

Authors:  Magdalena Skóra; Małgorzata Bulanda; Tomasz Jagielski
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

5.  The Brief Case: Scopulariopsis Endocarditis-a Case of Mistaken Takayasu's Arteritis.

Authors:  Miguel A Arroyo; Timothy B Walls; Ryan F Relich; Thomas E Davis; Bryan H Schmitt
Journal:  J Clin Microbiol       Date:  2017-09       Impact factor: 5.948

6.  Fatal invasive infection with fungemia due to Microascus cirrosus after heart and lung transplantation in a patient with cystic fibrosis.

Authors:  Charline Miossec; Florent Morio; Thierry Lepoivre; Patrice Le Pape; Dea Garcia-Hermoso; Françoise Gay-Andrieu; Alain Haloun; Michele Treilhaud; François Leclair; Michel Miegeville
Journal:  J Clin Microbiol       Date:  2011-05-04       Impact factor: 5.948

7.  Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds.

Authors:  Frédéric Lamoth; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2015-07-22       Impact factor: 5.948

8.  In Vitro Triple Combination of Antifungal Drugs against Clinical Scopulariopsis and Microascus Species.

Authors:  Limin Yao; Zhe Wan; Ruoyu Li; Jin Yu
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

9.  Interface Scopulariopsis gracilis fungal keratitis following Descemet's stripping automated endothelial keratoplasty (DSAEK) with a contaminated graft.

Authors:  Craig Wilde; Marco Messina; Tara Moshiri; Susan E Snape; Senthil Maharajan
Journal:  Int Ophthalmol       Date:  2017-09-12       Impact factor: 2.031

10.  Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Maria J Buitrago; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.